Looking positive.
" In animals in which GvHD was induced, the control animals survived for a median of just 24.5 days. However, treatment with CYP-001 markedly prolonged survival with the median survival time being 48 days and 57 days, respectively, in recipients of a single dose or dual doses of CYP-001"
Basically doubled their survival time.
"The mechanistic studies in the second stage of the study generated a substantial body of data, including evidence that CYP-001 treatment significantly decreased the percentage of CD4 and CD8 T cells infiltrating the bone marrow. This finding is noteworthy as infiltration of the bone marrow by CD4/CD8 cells is considered to be a key driver of GvHD, in this pre-clinical model. Full details of these findings will be described in a manuscript submitted to a leading peer-reviewed journal."
- Forums
- ASX - By Stock
- CYP
- Ann: Final GvHD Preclinical Report Confirms Treatment Benefit
Ann: Final GvHD Preclinical Report Confirms Treatment Benefit, page-2
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $37.01M |
Open | High | Low | Value | Volume |
20.5¢ | 20.5¢ | 20.5¢ | $480 | 2.343K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15128 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 43657 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15128 | 0.195 |
3 | 121013 | 0.190 |
3 | 15055 | 0.180 |
2 | 5997 | 0.175 |
1 | 50000 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 43657 | 1 |
0.210 | 60000 | 1 |
0.220 | 1875 | 1 |
0.240 | 10000 | 1 |
0.250 | 52225 | 2 |
Last trade - 15.39pm 02/09/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |